Rybelsus FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 6, 2020.
FDA Approved: Yes (First approved September 20, 2019)
Brand name: Rybelsus
Generic name: semaglutide
Dosage form: Tablets
Company: Novo Nordisk
Treatment for: Diabetes, Type 2
Rybelsus (semaglutide) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults with type 2 diabetes mellitus.
Development timeline for Rybelsus
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.